MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
22.64
+0.35
+1.57%
After Hours: 22.64 0 0.00% 19:34 07/21 EDT
OPEN
22.37
PREV CLOSE
22.29
HIGH
22.72
LOW
22.10
VOLUME
1.19M
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
9.38
MARKET CAP
2.01B
P/E (TTM)
-8.0880
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)
TipRanks · 33m ago
Is Syndax (SNDX) Quietly Redefining Its R&D Focus With New Menin and EGFR Programs?
Simply Wall St · 4h ago
Weekly Report: what happened at SNDX last week (0713-0717)?
Weekly Report · 2d ago
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst
TipRanks · 2d ago
Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story
Simply Wall St · 5d ago
Analysts’ Top Healthcare Picks: Lineage Therap (LCTX), Syndax Pharmaceuticals (SNDX)
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuticals (RYTM)
TipRanks · 6d ago
Syndax: Expanding Pipeline and Upcoming Axatilimab IPF Data Support Buy Rating and $29 Price Target Upside
TipRanks · 6d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.